Affiliations of authors: A. W. Blackstock, Wake Forest University School of Medicine, Winston-Salem, NC, and University of North Carolina at Chapel Hill, Chapel Hill, NC; J. E. Herndon II, Cancer and Leukemia Group B Statistical Center, Duke University, Durham, NC; E. D. Paskett, Wake Forest University School of Medicine; M. C. Perry, University of Missouri/Ellis Fischel Cancer Center, Columbia; S. L. Graziano, SUNY Upstate Medical University, Syracuse, NY; J. J. Muscato, Missouri Cancer Associates, Columbia; M. P. Kosty, Scripps Clinic, La Jolla, CA; W. L. Akerley, Women and Infants Hospital of Rhode Island, Providence; J. Holland, Memorial Sloan-Kettering Cancer Center, New York, NY; S. Fleishman, Institute of Oncology, Long Island Jewish Medical Center, New Hyde Park, NY; M. R. Green, Medical University of South Carolina, Charleston.
Correspondence to: A. William Blackstock, M.D., Department of Radiation Oncology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157 (e-mail: ablackst{at}wfubmc.edu).
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The prognosis for patients with advanced NSCLC is related to several factors, including pretreatment stage, sex, weight loss, and overall performance status (1419). In addition, it has been proposed that NSCLC in African-American patients is a biologically more aggressive disease because of a number of genetic factors (20). Race/ethnicity, in and of itself, however, may not be important in determining the prognosis for patients diagnosed with lung cancer. It is possible that the poor outcome observed for African-American patients may be reduced or eliminated by adjusting for comorbid conditions and socioeconomic factors associated with race/ethnicity.
In this study, we examined survival after treatment of advanced NSCLC among African-American and non-African-American patients participating in phase II or phase III Cancer and Leukemia Group B (CALGB) clinical trials. The cooperative group trial design defines the extent of disease at the time of study entry and provides for uniform therapy, thereby controlling for two major confounding factors affecting prognosis and allowing investigation of other determinants of prognosis. The mandate of the National Institutes of Health (NIH) Revitalization Act of 1993 required that all NIH-sponsored clinical trials include minorities and women in sufficient numbers to allow valid subset analysis to ascertain differences in the effect of treatments among women and minority participants (21). Our analysis in this study is an attempt to fulfill the intent of the mandate in a rational and ethically sound manner.
![]() |
PATIENTS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
During the period from 1989 through 1998, the CALGB conducted five consecutive phase II/III clinical trials evaluating systemic chemotherapy as an initial treatment for 529 patients with advanced NSCLC. In this study, we retrospectively evaluated the database from these five trials. A majority of patients outlined in these CALGB trials completed an extensive demographic questionnaire, which provided information on level of education, total yearly income, medical coverage, and marital/employment status.
The five CALGB protocols were protocols 8931, 8932, 9132, 9532, and 9731. During the period from July 1989 through February 1991, 291 patients with American Joint Committee on Cancer stage IIIB or IV NSCLC were accrued to protocol 8931, a randomized placebo-controlled phase III trial that assessed the impact of adding hydrazine sulfate to the standard chemotherapy regimen of cisplatin and vinblastine (22). During the period from February 1989 through June 1990, 40 patients were accrued to protocol 8932, a phase II study that evaluated the efficacy of cisplatin and intravenous etoposide for the treatment of metastatic or recurrent NSCLC (23). During the period from July 1991 through March 1992, 101 patients with stage IIIB or IV NSCLC were accrued to protocol 9132, a randomized phase II study that determined the efficacy of ifosfamide, mesna, cisplatin, and granulocyte colony-stimulating factor (G-CSF) or etoposide, cisplatin, and G-CSF (24). During the period from July 1995 through July 1996, 83 patients were accrued to protocol 9532, a randomized phase II study that evaluated the efficacy of paclitaxel and ifosfamide versus vinorelbine and ifosfamide for patients with stage IV or recurrent NSCLC (25). During the period from July 1997 through April 1998, 39 patients were accrued to CALGB protocol 9731, a phase II study that evaluated the efficacy and toxicity of weekly paclitaxel for patients with chemotherapy-naive, stage IIIB or stage IV NSCLC (26).
All patients had an Eastern Cooperative Oncology Group performance status of 0 or 1 and adequate renal and hepatic functions. No patient received systemic chemotherapy before entry into the study. Additional details of the design of the studies and primary findings can be found elsewhere (2226).
For inclusion in this analysis, we selected all protocol-eligible patients with follow-up information whose race was reported (442 Caucasian, five Hispanic, three Asian, one Native American, one Asian Indian, two Filipino, 46 African-American, and four not otherwise specified). Patients who were not considered eligible in the original analyses (2226) and registered patients who withdrew from the study before receiving the protocol treatment are not included in this study. The current analysis did not differentiate between the two treatment arms in CALGB protocol 8931 because the primary analyses of that study showed almost superimposable survival curves (22). Although 529 eligible patients are included in this article, data were missing for 25 patients. Thus, the multivariate survival analyses use data from 504 patients, of which 458 were non-African-American and 46 were African-American patients.
To address the impact of potential socioeconomic factors on treatment outcome, an additional analysis was performed on patients from CALGB protocols 8931, 9532, and 9731. Information was available from 300 non-African-Americans and 30 African-American patients regarding marital status, employment, educational level, insurance, and income for patients treated on these three trials. Information was not available for patients treated on CALGB protocols 8932 and 9132.
Study Endpoints and Statistical Methods
Frequency distributions of selected clinical variables (Table 1) were compared between African-Americans and non-African-Americans by chi-square and Fisher's exact tests. The Cox proportional hazards model was used to compute relative risk ratios for African-Americans versus non-African-Americans and to simultaneously assess and control for the confounding influence of other prognostic covariables (27,28). P values from these analyses are two-sided. After adjustment for known prognostic factors and other potential confounders, a variable describing race/ ethnicity (African-American versus non-African-American) was added to the model to determine whether its inclusion strengthened the model. For a subset of patients with socioeconomic data, chi-square tests were used to determine the relationship between socioeconomic measurements and race/ethnicity. Survival times were estimated with the use of KaplanMeier curves and were compared by a two-sided log-rank test using the SAS 6.09 and S-plus statistical package (SAS Institute, Inc., Cary, NC) (29,30).
|
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We determined the survival estimates for all patients across all protocols by the KaplanMeier method (29,30). Although the relative proportion of non-African-Americans and African-Americans differed by trial, the relative prognosis for the two race/ethnic groups did not differ. Without adjustment for other prognostic covariables, the survival pattern for non-African-Americans and African-Americans was statistically significantly different (P = .03). The 1-year survival rate was 30% (95% CI = 26% to 35%) for non-African-Americans and 22% (95% CI = 13% to 38%) for African-Americans (Fig. 1). The median survival for non-African-Americans and African-Americans was 7.9 and 7.7 months, respectively.
|
|
A statistically significant relationship was observed between race/ethnicity and several clinical factors included in the multivariate model. Although not statistically significant (P = .06), the percentage of patients presenting with weight loss of greater than or equal to 5% was greater among African-American patients than among non-African-American patients (RR = 1.28; 95% CI = 1.03 to 1.59). The percentage of patients with a performance status of 1 was also statistically significantly greater among the African-American patients (83%) than among the non-African-American patients (60%) (P = .002).
Table 3 summarizes the relationship between race/ethnicity and socioeconomic measurements within the subgroup of patients for whom the information was available. A comparison of marital status found that 58% of African-Americans were unmarried versus 27% of non-African-American patients. More African-American patients were disabled or unemployed (31% and 17%, respectively) than non-African-American patients (15% and 7%, respectively). African-American patients were more likely than non-African-American patients to receive Medicaid (P = .001) and less likely to have private group health insurance (P = .037) and had a substantially lower median income when compared with non-African-American patients (Table 3
).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In this cohort of 504 patients treated with chemotherapy for advanced NSCLC, the 46 African-Americans and 458 non-African-Americans had similar clinical stages of disease at the time of protocol entry. However, the percentage of patients with a performance status of 1 and/or with greater than or equal to 5% weight loss was higher among African-Americans than among non-African-Americans (83% African-Americans versus 60% non-African-Americans with a performance status of 1; 41% African-Americans versus 27% non-African-Americans with 5% weight loss). These parameters, which may be perhaps indicators of delayed access to cancer care, are known predictors for poor outcome in patients with NSCLC. The 1-year survival rate observed in the African-American patient cohort was 22%, which was marginally better than that achieved for patients receiving the best supportive care in other trials in advanced NSCLC (35). In our analysis, the 1-year survival rate for non-African-American patients was 30%, a statistically significantly higher survival rate than that for African-Americans. Being African-American did not, however, predict for worse survival above and beyond the clinical factors of diminished performance status or pretreatment weight loss. The 1-year survival rate for patients with a performance status of 1 across both African-American and non-African-American cohorts was comparable, supporting our postulate that equal treatment of racially diverse patients with equivalent pretreatment prognostic features results in equal outcome.
Perhaps the most important observation in our analysis is the relationship among poor performance status, low socioeconomic status, and the overall outcome observed in African-American patients. Table 3 shows that African-American patients were more likely to be unmarried, to be uninsured or rely upon Medicaid, and, in general, to have a lower income. All of these factors have been shown to predict a poor clinical outcome irrespective of race/ethnicity in a variety of diseases (3639). In our study population, African-American patients were also more likely at study entry to have a lower performance status, as a result of either their malignancy or other pre-existing comorbidities. Cancer patients with even moderately impaired ambulation or pain at diagnosis have reduced survival and greatly increased toxicity from chemotherapy when compared with patients who have a better performance status (4043). It is then reasonable to conclude that the survival of African-American patients with advanced NSCLC is not related to race/ethnicity or to inherent differences in the biology of their cancers; it is related to the clinical features at presentation that reflect an increase in the overall tumor burden (i.e., performance status and weight loss) at the time treatment is initiated.
From our analysis, we suggest that for low-income patients, social circumstances lead to a lack of resources and knowledge, poor living conditions, and a lack of access to care services that influence treatment efficacy or toxicity. Because equal treatment yields equal outcome among patients with the same stage of disease regardless of race/ethnicity, continued efforts are needed to encourage disease awareness, promote early detection, and increase minority participation in clinical trials. Ultimately, potential interventions need to be introduced that will decrease the mortality for all patients diagnosed with advanced NSCLC.
|
![]() |
NOTES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The research for these Cancer and Leukemia Group B studies (protocols 8931, 8932, 9132, 9532, and 9731) was supported, in part, by Public Health Service grant CA31946 from the National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, to the Cancer and Leukemia Group B (Richard L. Schilsky, M.D., Chairman), and GlaxoSmithKline (Research Triangle Park, NC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCI.
We thank Carrie E. Blackstock, Ph.D. (University of North Carolina, Chapel Hill), for her editorial support.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1
Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:733.
2 Reis L, Kosary C, Hankey B. SEER cancer statistics review, 19731996. Bethesda (MD): National Cancer Institute; 1999.
3
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899909.
4 Cellerino R, Tummarello D, Guidi F, Isidori P, Raspugli M, Biscottini B, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991;9:145361.[Abstract]
5 Cormier Y, Bergeron D, La Forge J, Lavandier M, Fournier M, Chenard J, et al. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer 1982;50:8459.[Medline]
6 Dhingra HM, Valdivieso M, Carr DT, Chiuten DF, Farha P, Murphy WK, et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16213 in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1985;3:17683.[Abstract]
7 Gadgeel S, Graff J, Kau Y, Severson R, Weiss L, Kalemkerian G. Racial differences in lung cancer patients: analysis of temporal trends using the metropolitan Detroit SEER database [abstract]. Proc ASCO 1999;18:1890.
8
Parker SL, Davis KJ, Wingo PA, Ries LA, Heath CW Jr. Cancer statistics by race and ethnicity. CA Cancer J Clin 1998;48:3148.
9
Wingo PA, Ries LA, Giovino GA, Miller DS, Rosenberg HM, Shopland DR, et al. Annual report to the nation on the status of cancer, 19731996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999;91:67590.
10 Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, et al. The annual report to the nation on the status of cancer, 19731997, with a special section on colorectal cancer. Cancer 2000;88:2398424.[Medline]
11 Miller BA, Kolonel LN, Bernstein L, Young JL, Swanson GM, West DW, Glover CS, Alexander GA, editors. Racial/ethnic patterns of cancer in the United States 1988-1992. Bethesda (MD): National Cancer Institute; 1996. NIH Publ No. 96-4104.
12 Young JL Jr, Ries LG, Pollack ES. Cancer patient survival among ethnic groups in the United States. J Natl Cancer Inst 1984;73:34152.[Medline]
13
Wingo PA, Bolden S, Tong T, Parker SL, Martin LM, Heath CW Jr. Cancer statistics for African Americans [published erratum appears in CA Cancer J Clin 1996 46:164]. CA Cancer J Clin 1996;46:11325.
14 Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:2532.[Medline]
15 Lanzotti VJ, Thomas DR, Boyle LE, Smith TL, Gehan EA, Samuels ML. Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria. Cancer 1977;39:30313.[Medline]
16 Green N, Kuroara SS, George FW 3rd. Cancer of the lung. An in-depth analysis of prognostic factors. Cancer 1971;28:122933.[Medline]
17 Sorensen JB, Olsen JE. Prognostic implications of histopathologic subtyping in patients with surgically treated stage I or II adenocarcinoma of the lung. J Thorac Cardiovasc Surg 1989;97:24551.[Abstract]
18 O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986;4:160414.[Abstract]
19 Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1986;4:7029.[Abstract]
20 Haque AK, Adegboyega P, Al-Salameh A, Vrazel DP, Zwischenberger J. p53 and P-glycoprotein expression do not correlate with survival in nonsmall cell lung cancer: a long-term study and literature review. Mod Pathol 1999;12:115866.[Medline]
21 Freedman LS, Simon R, Foulkes MA, Friedman L, Geller NL, Gordon DJ, et al. Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993the perspective of NIH clinical trialists. Control Clin Trials 1995;16:27785; discussion 2869, 293309.[Medline]
22 Kosty MP, Fleishman SB, Herndon JE 2nd, Coughlin K, Kornblith AB, Scalzo A, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994;12:111320.[Abstract]
23 Muscato JJ, Cirrincione C, Clamon G, Perry MC, Omura G, Berkowitz I, et al. Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. Lung Cancer 1995;13:28594.[Medline]
24 Graziano SL, Valone FH, Herndon JE 2nd, Crawford J, Richards F 2nd, Rege VB, et al. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 1996;14:31529.[Medline]
25 Perry MC, Ihde DC, Herndon JE 2nd, Grossbard ML, Grethein SJ, Atkins JN, et al. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer 2000;28:638.[Medline]
26 Akerley W, Herndon JE, Egorin MJ, Lyss A, Kindler H, Savarese D, et al. CALGB 9731: phase II trial of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC) [abstract]. Proc ASCO 1999;18:1783.
27 Cox D. Regression models and life tables. J R Stat Soc 1972;34:187220.
28 Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:54154.[Medline]
29 Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:45781.
30 Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:16370.[Medline]
31 Fry WA, Menck HR, Winchester DP. The National Cancer Data Base report on lung cancer. Cancer 1996;77:194755.[Medline]
32 Ries LA. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol 1994;10:2130.[Medline]
33 Greenwald HP, Polissar NL, Borgatta EF, McCorkle R, Goodman G. Social factors, treatment, and survival in early-stage non-small cell lung cancer. Am J Public Health 1998;88:16814.[Abstract]
34 Coates RJ, Bransfield DD, Wesley M, Hankey B, Eley JW, Greenberg RS, et al. Differences between black and white women with breast cancer in time from symptom recognition to medical consultation. Black/White Cancer Survival Study Group. J Natl Cancer Inst 1992;84: 93850.[Abstract]
35 Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancera randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000;83:44753.[Medline]
36 Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 1991;67:31315.[Medline]
37 Herndon JE 2nd, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 1999;85:33340.[Medline]
38 Loprinzi CL, Laurie JA, Wieand HS, Krook JE, Novotny PJ, Kugler JW, et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol 1994;12:6017.[Abstract]
39
Roetzheim RG, Pal N, Tennant C, Voti L, Ayanian JZ, Schwabe A, et al. Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst 1999;91:140915.
40 Lopez PG, Stewart DJ, Newman TE, Evans WK. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group. Cancer Prev Control 1997;1:1827.[Medline]
41 Ettinger DS, Cox JD, Ginsberg RJ, Komaki R, Kris MG, Livingston RB, et al. NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10:81111.[Medline]
42 Desch CE, Penberthy L, Newschaffer CJ, Hillner BE, Whittemore M, McClish D, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care 1996;34:15262.[Medline]
43 Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986;4:1422.[Abstract]
Manuscript received May 3, 2001; revised December 14, 2001; accepted December 18, 2001.
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |